Omega-backed startup sells itself quietly; AbbVie breaks out more Rinvoq data; Revance gets FDA date for Botox rival
→ When it came into the limelight with a $35 million Series A financing in 2018, Attenua promised to repurpose three oral neuronal nicotinic …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
